How to deal with Pazopanib resistance

Pazopanib (Pazopanib) is an oral multi-target tyrosine kinase inhibitor widely used to treat malignant tumors such as renal cell carcinoma and soft tissue sarcoma. For patients treated with pazopanib, it is critical to regularly monitor tumors for biomarker and imaging changes. This helps to detect signs of resistance early and to take appropriate treatment measures in a timely manner. When patients develop resistance to pazopanib, they should communicate with their doctor promptly, and the doctor may recommend trying to replace it with other effective targeted drugs. Such as sorafenib, axitinib, etc. may be commonly used alternative drug options.